Search Results - "Henner, William R."

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors by Luke, Jason J, Barlesi, Fabrice, Chung, Ki, Tolcher, Anthony W, Kelly, Karen, Hollebecque, Antoine, Le Tourneau, Christophe, Subbiah, Vivek, Tsai, Frank, Kao, Steven, Cassier, Philippe A, Khasraw, Mustafa, Kindler, Hedy L, Fang, Hua, Fan, Frances, Allaire, Kathryn, Patel, Maulik, Ye, Shiming, Chao, Debra T, Henner, William R, Hayflick, Joel S, McDevitt, Michael A, Fong, Lawrence

“…BackgroundCD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to…”
Get full text

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency by Yen, Wan-Ching, Fischer, Marcus M, Axelrod, Fumiko, Bond, Christopher, Cain, Jennifer, Cancilla, Belinda, Henner, William R, Meisner, Rene, Sato, Aaron, Shah, Jalpa, Tang, Tracy, Wallace, Breanna, Wang, Min, Zhang, Chun, Kapoun, Ann M, Lewicki, John, Gurney, Austin, Hoey, Timothy

“…The Notch pathway plays an important role in both stem cell biology and cancer. Dysregulation of Notch signaling has been reported in several human tumor…”
Get full text

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC by Peterlin, Pierre, Saada-Bouzid, Esma, Moskovitz, Mor, Pigneux, Arnaud, Yuda, Junichiro, Sinnollareddy, Mahipal, Henner, William R., Chen, Diana, Freise, Kevin J., Leibman, Rachel S., Avigdor, Abraham, Shimizu, Toshio

Get full text

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies by Levy, Moshe, Gustafson, Carl, Purcell, James, Freise, Kevin J., Assaily, Wissam, Brackman, Deanna, Henner, William R., McDevitt, Michael, Kuruvilla, John

Get full text

A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors by Powderly, John D., Tolcher, Anthony, LoRusso, Patricia, Blaney, Martha Elizabeth, Dacosta, Daniel, Henner, William R, McDevitt, Michael Anthony, Miller, Kathy D., Golan, Talia

“…Abstract only TPS3147 Background: CD40 is a key costimulatory molecule for both the innate and adaptive immune systems that is essential for T-cell activation…”
Get full text

Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer by Avigdor, Abraham, Peterlin, Pierre, Yuda, Junichiro, Moskovitz, Mor Tal, Gabrail, Nashat Y., Moshe, Yakir, Quesnel, Bruno, Henner, William R, Reilly, Edward B., Huang, Donghui, Kovalenko, Maria, Parikh, Apurvasena, Jaryno, Stacy, Leibman, Rachel S, Freise, Kevin J, Saada-Bouzid, Esma, Shimizu, Toshio

“…Abstract only TPS2674 Background: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive therapeutic target in cancer, due to its…”
Get full text

Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors by Fang, Hua, Ye, Shiming, Reddy, Anita, Turan, Tolga, Woolley, Andrew, Chao, Debra T., Ramathal, Cyril, Henner, William R., Hew, Kinjal, McDevitt, Michael, Hayflick, Joel, Fan, Frances, Allaire, Kathryn, Fong, Lawrence

“…Abstract Background: ABBV-428 is a first-in-class bispecific antibody against CD40 and MSLN designed to stimulate CD40 for tumor-specific immune activation…”
Get full text

Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients by Zhang, Chun, Henner, William R., Wang, Min, Cattaruzza, Fiore, Yeung, Pete, O'Young, Gilbert, Liu, Yuwang, Argast, Gretchen, Xu, Lu, Uttamsingh, Shailaja, Lewicki, John, Kapoun, Ann M.

“…Abstract Introduction: We have developed a monoclonal antibody, vantictumab, that blocks canonical Wnt/β-catenin signaling through binding of five FZD…”
Get full text